编者按

2025年美国临床肿瘤学会年会（ASCO）将于美国东部时间（GMT-5）5月30日至6月3日在芝加哥召开。本次会议聚焦肿瘤治疗前沿，将呈现化疗、内分泌治疗、免疫治疗、靶向治疗及精准医学的最新进展。肿瘤瞭望消化时讯特别整理本届大会消化道肿瘤领域的重要研究进展，供读者参考，如有缺漏和错误，欢迎留言指正。

Oral Abstract Session

上消化道肿瘤篇 

报告时间：GMT-5 15:00-15:36（5月31日）；GMT+8 04:00-04:36（6月1日）

报告地点：Hall D1

摘要号：4000

标题：Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): First results of overall survival (OS) from CheckMate 577.

在新辅助放化疗（CRT）后已切除的食管癌或食管胃交界癌（EC/GEJC）中使用纳武利尤单抗作为辅助治疗：来自CheckMate 577研究的总生存期（OS）初步结果。

讲者：Ronan Joseph Kelly, MD, MBA, FASCO

摘要号：LBA4002

标题：Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study.

德曲妥珠单抗（T-DXd）对比雷莫西尤单抗（RAM）联合紫杉醇（PTX）用于人表皮生长因子受体2阳性（HER2+）不可切除/转移性胃癌（GC）或胃食管交界腺癌（GEJA）患者的二线治疗：随机Ⅲ期DESTINY-Gastric04研究的初步分析。

讲者：Kohei Shitara, MD

摘要号：4003

标题：Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01).

Claudin18.2特异性CAR T细胞（Satri-cel）对比医生选择的治疗方案应用于既往接受过治疗的晚期GC/GEJC患者：随机、开放标签、Ⅱ期CT041-ST-01试验的主要结果。

讲者：齐长松|北京大学肿瘤医院

摘要号：LBA4004

标题：Results of a randomized phase Ⅲ trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-Ⅲ pancreatic ductal adenocarcinoma.

一项关于 I ~ Ⅲ期胰腺导管腺癌术前采用mFOLFIRINOX或PAXG 方案进行化疗的随机Ⅲ期试验结果。

讲者：Michele Reni, MD

摘要号：LBA4005

标题：PANOVA-3: Phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC).

PANOVA-3：吉西他滨和白蛋白结合型紫杉醇治疗局部晚期胰腺导管腺癌的Ⅲ期研究（TTFields）

讲者：Vincent J. Picozzi, MD, MMM

摘要号：4006

标题：Preliminary results from the randomized phase 2 study (1801 part 3B) of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) versus GnP alone in patients (pts) with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).

elraglusib联合吉西他滨/白蛋白结合型紫杉醇（GnP）方案 vs. 单纯GnP方案治疗未经治转移性胰腺导管腺癌（mPDAC）患者的随机Ⅱ期研究（1801研究3B部分）初步结果。

讲者：Devalingam Mahalingam, MD, PhD

摘要号：4007

标题：A phase Ⅲ randomized clinical trial evaluating perioperative therapy (neoadjuvant chemotherapy versus chemoradiotherapy) in locally advanced gallbladder cancers (POLCAGB).

一项评估局部晚期胆囊癌围手术期治疗（新辅助化疗对比放化疗）的Ⅲ期随机临床试验（POLCAGB研究）

讲者：Reena Engineer, DNB

摘要号：4008

标题：Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone followed adjuvant therapy in biliary tract cancer: Final results from the phase Ⅲ AIO/CALGP/ACO-GAIN-Trial.

吉西他滨联合顺铂新辅助化疗后行根治性肝切除术对比单纯立即行根治性肝切除术继以辅助治疗用于胆道癌：Ⅲ期AIO/CALGP/ACO-GAIN试验的最终结果。

讲者：Thorsten Oliver Goetze

下消化道肿瘤

报告时间：GMT-5 14:45-17:09（5月30日）；GMT+8 03:45-06:09（5月31日）

报告地点：Arie Crown Theater

摘要号：LBA3500

标题：First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): Progression-free survival and updated overall survival analyses.

用于BRAF V600E突变型转移性结直肠癌的一线治疗方案：encorafenib+西妥昔单抗+mFOLFOX6（BREAKWATER研究）：无进展生存期及更新后的总生存期分析。

讲者：Elena Elez, MD, PhD

摘要号：3501

标题：Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) or NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded analyses from CheckMate 8HW.

纳武利尤单抗联合伊匹木单抗对比化疗或纳武利尤单抗单药治疗微卫星高度不稳定/错配修复缺陷（MSI-H/dMMR）的转移性结直肠癌（mCRC）：来自CheckMate 8HW研究的拓展性分析

讲者：Heinz-Josef Lenz, MD

摘要号：LBA3502

标题：Anlotinib versus bevacizumab added to standard first-line chemotherapy among patients with RAS/BRAF wild-type, unresectable metastatic colorectal cancer: A multicenter, prospective, randomised, phase 3 clinical trial (ANCHOR trial).

安罗替尼对比贝伐珠单抗联合一线标准化疗应用于RAS/BRAF野生型、不可切除的转移性结直肠癌：一项多中心、前瞻性、随机、Ⅲ期临床试验（ANCHOR）。

讲者：丁克峰，浙江大学医学院附属第二医院

摘要号：3503

标题：ctDNA-guided adjuvant chemotherapy escalation in stage Ⅲ colon cancer: Primary analysis of the ctDNA-positive cohort from the randomized AGITG dynamic-Ⅲ trial (intergroup study of AGITG and CCTG).

基于循环肿瘤DNA（ctDNA）指导的Ⅲ期结肠癌辅助化疗强化：来自随机AGITG dynamic-Ⅲ试验（AGITG和CCTG的组间研究）中ctDNA阳性队列的初步分析。

讲者：Jeanne Tie, MD, FRACP, MBChB 

摘要号：3504

标题：Tissue-free circulating tumor DNA assay and patient outcome in a phase Ⅲ trial of FOLFOX-based adjuvant chemotherapy (Alliance N0147).

在一项基于FOLFOX方案的辅助化疗Ⅲ期试验（Alliance N0147试验）中无组织循环肿瘤DNA检测与患者预后情况。

讲者：Frank A. Sinicrope, MD

摘要号：3505

标题：Perioperative systemic therapy for resectable colorectal peritoneal metastases: A multicenter randomized phase 3 trial (CAIRO6).

可切除的结直肠腹膜转移癌的围手术期系统治疗：一项多中心随机Ⅲ期试验（CAIRO6试验）。

讲者：Ignace De Hingh, MD, PhD

摘要号：3506

标题：Long-term safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 (phase 1b).

sotorasib联合panitumumab及FOLFIRI方案用于既往接受过治疗的KRAS G12C突变型转移性结直肠癌（mCRC）的长期安全性和有效性：CodeBreaK 101研究（Ib期）。

讲者：John H. Strickler, MD

摘要号：3507

标题：Efficacy and safety of olomorasib, a second-generation KRAS G12C inhibitor, plus cetuximab in KRAS G12C-mutant advanced colorectal cancer.

第二代KRAS G12C抑制剂olomorasib联合西妥昔单抗治疗KRAS G12C突变型晚期结直肠癌的疗效与安全性。

讲者：Antoine Hollebecque, MD

摘要号：3508

标题：The KRAS G12C inhibitor MK-1084 for KRAS G12C–mutated advanced colorectal cancer (CRC): Results from KANDLELIT-001.

KRAS G12C抑制剂MK - 1084用于KRAS G12C突变的晚期结直肠癌（CRC）：来自KANDLELIT - 001研究的结果。

讲者：Iwona A. Lugowska, MD, PhD

Rapid Oral Abstract Session

上消化道肿瘤

报告时间：GMT-5 11:30-12:06（6月2日）；GMT+8 00:30-01:06（6月3日）

报告地点：Hall D2

摘要号：LBA4012

标题：Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (C)/trastuzumab (Tra) as first-line (1L) treatment of patients (pts) with HER2-expressing locally advanced or metastatic (la/m) gastric cancer.

维迪西妥单抗联合特瑞普利单抗和化疗/曲妥珠单抗作为局部晚期或转移性HER2表达胃癌患者的一线（1L）治疗。

讲者：沈琳，北京大学肿瘤医院

摘要号：4013

标题：Long-term outcomes and overall survival (OS) for zanidatamab + chemotherapy in HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinoma (mGEA): 4-year follow-up of a phase 2 trial.

在人表皮生长因子受体2阳性（HER2+）晚期或转移性胃食管腺癌（mGEA）中，zanidatamab联合化疗的长期结局和总生存期（OS）：一项Ⅱ期试验的4年随访结果。

讲者：Elena Elimova, MD

摘要号：4014

标题：Recurrence patterns in the prospective, randomized, controlled, multicenter phase Ⅲ ESOPEC trial comparing perioperative chemotherapy with preoperative chemoradiotherapy in patients with esophageal adenocarcinoma.

在一项前瞻性、随机、对照、多中心的Ⅲ期ESOPEC试验中，比较食管腺癌患者围手术期化疗与术前放化疗的复发模式。

讲者：Jens Hoeppner, MD, FAChirg, FACS

摘要号：4015

标题：Decoding the response and resistant features to the Claudin18.2-specific CAR-T cell CT041 in gastric cancer: A multi-omics exploratory biomarker analysis of the phase 1 clinical trial.

揭秘胃癌中Claudin18.2特异性CAR-T细胞CT041的应答和耐药性特征：Ⅰ期临床试验的多组学探索性生物标志物分析。

讲者：彭昊昕，北京大学肿瘤医院

摘要号：4016

标题：Cosiporfin sodium (DVDMS)-mediated photodynamic therapy (PDT) versus treatment of physician’s choice (TPC) in patients (pts) with advanced esophageal cancer (aEC): A phase Ⅲ, randomized, open-label, multicenter trial.

华卟啉钠介导的光动力疗法（PDT）对比医师选择治疗（TPC）治疗晚期食管癌患者：一项Ⅲ期、随机、开放标签、多中心试验。

讲者：周军，北京大学肿瘤医院

摘要号：4017

标题：Claudin18.2 (CLDN18.2) expression and efficacy in pancreatic ductal adenocarcinoma (PDAC): Results from a phase I dose expansion cohort evaluating IBI343.

Claudin18.2在胰腺导管腺癌中的表达和疗效：来自评估IBI343的Ⅰ期研究剂量扩展队列的结果。

讲者：虞先濬，复旦大学附属肿瘤医院

摘要号：4018

标题：Clinical activity of EBC-129, a first-in class, anti N256-glycosylated CEACAM5 and CEACAM6 antibody-drug conjugate (ADC), in patients with pancreatic ductal adenocarcinoma (PDAC) in a phase 1 study.

同类首创抗N256糖基化癌胚抗原相关细胞黏附分子5（CEACAM5）和癌胚抗原相关细胞黏附分子6（CEACAM6）抗体偶联药物（ADC）EBC - 129，在胰腺导管腺癌（PDAC）患者中的Ⅰ期临床活性研究。

讲者：Robert William Lentz, MD

摘要号：4019

标题：10-year follow up of a phase 2 clinical trial of pembrolizumab (pembro) in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors.

帕博利珠单抗用于微卫星高度不稳定（MSI-H）/错配修复缺陷（dMMR）晚期实体瘤的一项Ⅱ期临床试验的10年随访结果。

讲者：Katherine M. Bever, MD

摘要号：4020

标题：Health-related quality of life (HRQOL) in the phase 3 trial of cabozantinib vs placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET, Alliance A021602).

CABINET研究：cabozantinib对比安慰剂治疗既往治疗后进展的晚期神经内分泌肿瘤（NET）的Ⅲ期试验（CABINET，Alliance A021602）中健康相关生活质量（HRQOL）分析。

讲者：Amylou C. Dueck, PhD

下消化道肿瘤

报告时间：GMT-5 11:30-12:42（6月1日）；GMT+8 00:30-01:42（6月2日） 

报告地点：Hall D1

摘要号：3512

标题：Upfront modified FOLFOXIRI plus panitumumab (pan) versus FOLFOX/pan for unresectable RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: Overall survival (OS) results from the phase Ⅲ TRIPLETE study by GONO.

初始使用改良的FOLFOXIRI方案联合panitumumab对比FOLFOX方案联合panitumumab治疗不可切除的RAS和BRAF野生型转移性结直肠癌（mCRC）患者：来自GONO开展的Ⅲ期TRIPLETE研究的总生存期（OS）结果。

讲者：Veronica Conca, MD

摘要号：3513

标题：FIRE-4 (AIO KRK-0114): Randomized study evaluating the efficacy of cetuximab re-challenge in patients with metastatic RAS wild-type colorectal cancer responding to first-line treatment with FOLFIRI plus cetuximab.

FIRE-4（AIO KRK-0114）研究：一项随机研究，旨在评估对于一线接受FOLFIRI方案联合西妥昔单抗治疗有反应的转移性RAS野生型结直肠癌患者，再次使用西妥昔单抗治疗的疗效。

讲者：Lena Weiss, MD

摘要号：3514

标题：Longitudinal ctDNA monitoring and prediction of anti-EGFR rechallenge outcomes in RAS/BRAF wild-type metastatic colorectal cancer (mCRC): The REMARRY & PURSUIT trials.

在RAS/BRAF野生型转移性结直肠癌（mCRC）中循环肿瘤DNA（ctDNA）的纵向监测以及对抗表皮生长因子受体（EGFR）再挑战治疗结局的预测：REMARRY和PURSUIT试验。

讲者：Yoshinori Kagawa, MD, PhD

摘要号：LBA3515

标题：Panitumumab retreatment followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA (ctDNA): Results of the phase II randomized PARERE trial by GONO.

在RAS和BRAF野生型循环肿瘤DNA（ctDNA）的化疗难治性转移性结直肠癌患者中，先使用panitumumab再治疗后序贯瑞戈非尼对比先使用瑞戈非尼后序贯panitumumab再治疗：来自GONO开展的Ⅱ期随机PARERE试验的结果。

讲者：Chiara Cremolini, MD, PhD

摘要号：LBA3516

标题：JMT101 in combination with irinotecan and SG001 versus regorafenib in patients with metastatic colorectal adenocarcinoma (mCRC): Results of a randomized, controlled, open-label, phase II study.

研究名称（中文）：JMT101联合伊立替康和SG001对比瑞戈非尼治疗转移性结直肠腺癌：一项随机、对照、开放标签、Ⅱ期研究的结果。

讲者：许剑民，复旦大学附属中山医院

摘要号：3517

标题：Phase 2 dose expansion study of DSP107, a first-in-class bi-specific 4-1BB T-cell engager, with and without atezolizumab in metastatic MSS colorectal cancer patients.

一项关于DSP107（一种同类首创的双特异性4-1BB T细胞衔接器）联合或不联合阿替利珠单抗用于转移性微卫星稳定（MSS）结直肠癌患者的Ⅱ期剂量扩展研究。

讲者：Anwaar Saeed, MD

摘要号：3518

标题：Circulating tumor DNA as an early response indicator in anal squamous cell carcinoma treated with chemoradiation.

循环肿瘤DNA作为接受放化疗的肛门鳞状细胞癌患者的早期疗效指标。

讲者：Aron Bercz, MD

摘要号：3519

标题：Short-course radiotherapy followed by sintilimab and CAPOX as total neoadjuvant treatment in locally advanced rectal cancer: A prospective, randomized controlled trial (SPRING-01).

短程放疗序贯信迪利单抗联合CAPOX作为局部晚期直肠癌患者的全程新辅助治疗：一项前瞻性、随机、对照试验（SPRING-01）。

讲者：靖昌庆，山东第一医科大学附属省立医院

摘要号：3520

标题：Proposed changes to the pathologic staging for colon cancer (CC): AJCC Colon Cancer Expert Panel (AJCCCCEP).

关于结肠癌（CC）病理分期的拟议修改建议：美国癌症联合委员会结肠癌专家小组（AJCCCCEP）。

讲者：Qian Shi, PhD

0